Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-083 in Recurrent Platinum Resistant Ovarian Cancer
NCT03281681Phase 2Withdrawn
- Sponsor
- DelMar Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dianhydrogalactitol in ovarian cancer, sponsored by DelMar Pharmaceuticals. Primary endpoint: Overall Response Rate at 6 months. Planned start Mar 2021; status: withdrawn.
02
Drugs
dianhydrogalactitol
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03281681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281681.